内容摘要：Gaming developer John O'Reilly, 28, noticed the systems in their local Tesco in Woolwich in south-east London, and wonders how anyone can consent to "such deeply invasive technology".

Gaming developer John O'Reilly, 28, noticed the systems in their local Tesco in Woolwich in south-east London, and wonders how anyone can consent to "such deeply invasive technology".

There are not many times when a single social media post can trigger a snowball effect which leads to a significant change in the law.But social media influencer Laura Young's actions did exactly that when she started noticing a litter problem while walking her dog in Dundee.

'Less waste Laura' - as she calls herself online - said she was "sick of litter picking" disposable vapes and wanted to campaign against them.Three years on and her campaign has led to a UK-wide ban now coming into force.Laura realised her message had struck a chord when a TikTok video she created was viewed 10.5 million times.

It led to a prominent newspaper campaign and then calls from government officials requesting meetings with ministers.She told BBC Scotland News: "If you look up disposable vapes, (mine) is the first (tweet) that comes up.

"Within five weeks it had made the headlines and of course everyone was showing where these vapes were."

The year after Laura first raised the issue, the Scottish government commissioned an urgent report into the impact of single use vapes on the environment and on young people.Researchers blame the treatment gap on weak health systems and limited access to effective antibiotics.

For example, only 103,647 full treatment courses were procured of Tigecycline across eight countries - far short of the 1.5 million patients who needed them, the study found. This highlighted a major shortfall in the global response to drug-resistant infections.What prevents patients with drug-resistant infections in India from getting the right antibiotics?

Physicians point to multiple barriers - reaching the right health facility, getting accurate diagnostic tests, and accessing effective drugs. Cost remains a major hurdle, with many of these antibiotics priced far beyond the reach of poorer patients."Those who can afford these antibiotics often overuse them; those who can't, don't get them at all," says Dr Gaffar. "We need a system that ensures access for the poor and prevents misuse by the well-to-do."